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Abstract
Autozygosity occurs when two chromosomal segments that are identical from a common ancestor are inherited from each
parent. This occurs at high rates in the offspring of mates who are closely related (inbreeding), but also occurs at lower
levels among the offspring of distantly related mates. Here, we use runs of homozygosity in genome-wide SNP data to
estimate the proportion of the autosome that exists in autozygous tracts in 9,388 cases with schizophrenia and 12,456
controls. We estimate that the odds of schizophrenia increase by,17% for every 1% increase in genome-wide autozygosity.
This association is not due to one or a few regions, but results from many autozygous segments spread throughout the
genome, and is consistent with a role for multiple recessive or partially recessive alleles in the etiology of schizophrenia.
Such a bias towards recessivity suggests that alleles that increase the risk of schizophrenia have been selected against over
evolutionary time.
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Introduction
Schizophrenia is a highly (.70–.80) heritable [1] neurodevelop-
mental disorder that has a lifetime prevalence of ,0.4% [2]. As
with most complex disorders, the specific genetic variants that
account for a majority of the heritability of schizophrenia remain
to be discovered. Two primary factors may explain the difficulty in
identifying risk variants. First, the results of genome-wide
association studies (GWAS) make it clear that a very large number
of genes contribute to schizophrenia risk, and the overall
population risk attributable to any one risk variant must be small
[3]. Second, although common causal variants almost certainly
play an important role in the genetic etiology of schizophrenia
[4,5], it is likely that the frequency distribution of schizophrenia
risk alleles is biased towards the rare end of the spectrum [5]. Both
of these factors are consistent with selection keeping schizophrenia
risk alleles with the largest effects rare, such that no single allele
can contribute much to population risk.
If schizophrenia risk alleles have been selected against across
evolutionary time (have been under ‘‘purifying’’ selection), another
prediction is that schizophrenia risk alleles will be biased towards
being recessive. This bias, called directional dominance, occurs in
traits subject to purifying selection because selection more
efficiently purges the additive and dominant alleles with the
strongest effects, leaving the remaining pool of segregating alleles
more recessive than otherwise expected [6]. Directional domi-
nance has traditionally been inferred from observations of
inbreeding depression, the tendency for offspring of close genetic
relatives to have higher rates of congenital disorders and lower
fitness [7]. Fitness traits such as survival, reproduction, resistance
PLoS Genetics | www.plosgenetics.org 1 April 2012 | Volume 8 | Issue 4 | e1002656
to disease, and predator avoidance tend to show more inbreeding
depression than traits under less intense selection [8]. Interestingly,
there are numerous reports of inbreeding effects on human
complex traits such as heart disease [9], hypertension [10],
osteoporosis [11], cancer [12], and IQ [13,14].
Studies that have investigated inbreeding effects on schizophre-
nia using pedigree data suggest that close (e.g., cousin-cousin)
inbreeding is a risk factor [15,16,17,18,19,20], although three
studies have failed to find the predicted effect [21,22,23].
However, close inbreeding cannot be a major contributor to
schizophrenia risk in industrialized countries given its rarity (,1%
of marriages) [24] and the modest increase in the odds of
schizophrenia among highly inbred offspring (,2- to 5-fold)
[15,16,17,18,19]. Nevertheless, inbreeding is a matter of degree;
when distant relatives are considered, everyone is inbred to some
degree. It is likely that the parents of the vast majority of people
alive today share a common ancestor within,15 generations [25].
Although such ‘‘distant’’ inbreeding would be prohibitively
difficult to detect from pedigrees, it can leave signals in the
genome that are detectable using genome-wide single nucleotide
polymorphism (SNP) data.
The inbreeding coefficient of an individual, F, is defined as the
probability that two randomly chosen alleles at a homologous
locus within an individual are identical by descent (IBD, identical
because they are inherited from a common ancestor) [26].
Homozygosity arising from the inheritance of two IBD genomic
segments is termed autozygosity. Most estimates of F assume that
marker data are independent, and provide an aggregate measure
of homozygosity at measured variants across the genome [27].
Recently, however, several investigators have used runs of
homozygosity (ROHs; long stretches of homozygous SNPs) to infer
autozygososity, and have investigated whether the proportion of
the genome that exists in such ROHs, Froh, predicts complex traits
[28,29,30,31,32,33,34,35].
Of several alternative estimates of F, including F estimated by
treating markers independently and F estimated from pedigree
information, Keller, Visscher, and Goddard [25] recently
concluded that Froh is optimal for inferring the degree of
genome-wide autozygosity and for detecting inbreeding effects.
However, given the small variation in genome-wide Froh in
unselected samples (e.g., SD ,.005), large sample sizes (e.g.,
.12,000) are necessary to detect inbreeding depression for likely
effect sizes in samples not selected for recent inbreeding [25].
Studies investigating the effects of Froh on human complex traits
with samples sizes ,3,000 and that failed to find significant
inbreeding effects [28,33,34,35,36] are likely to have been
underpowered. That said, the only study of Froh in schizophrenia
[29] found a very large inbreeding effect, but the effect was
observed in a small sample (n=322) and was significant only for
ROHs caused by common haplotypes.
The present study uses imputed SNP data from 17 schizophre-
nia case-control datasets (total N=21,844) that are part of the
Psychiatric GWAS Consortium (PGC) [3,37] to investigate
whether Froh is associated with higher risk of schizophrenia. We
also use an ROH mapping approach to investigate whether
specific areas of the genome are predictive of case-control status
when autozygous. This study represents the largest investigation to
date on the potential consequences of autozygosity as estimated
using Froh, and may help elucidate the genetic architecture and
natural history of schizophrenia.
Results
SNP data from 9,388 schizophrenia cases and 12,456 controls
were collected with institutional review board approval from 17
sites in 11 countries (Table 1). Due to the different SNP platforms
used across datasets, the number of SNPs remaining after quality
control and linkage-disequilibrium pruning procedures (see below)
differed substantially between the datasets (column 6 of Table 1).
This induced artifactual differences in ROH statistics across
datasets and made it impossible to allelically match ROHs across
datasets (see Methods). To circumvent these issues, our main
analysis concentrated on ROH results from a common set of
imputed SNPs, but we also report results from the raw (non-
imputed) SNP data. We imputed 1,252,901 autosomal SNPs in
each dataset using BEAGLE [38] and HapMap3 as the reference
panel [3]. We used extremely stringent imputation QC thresholds
that have been shown to achieve accuracy rates similar to those in
genotyped SNPs [39], leaving 398,325 high-quality imputed SNPs.
We then removed 303,513 SNPs that were in high linkage
disequilibrium (LD) with other SNPs. We defined ROHs as being
$65 consecutive homozygous SNPs in a row (,2.3 Mb) among
the remaining 94,812 imputed SNPs [40]. We followed the same
procedure for each dataset using the raw data, but defined ROHs
as being $110 consecutive homozygous SNPs in a row (,1.7 to
,3.2 Mb, depending on the dataset). ROH thresholds were
determined empirically (see Methods) so as to maximize the
significance of the schizophrenia-Froh relationship, but as shown
below, results differed little for alternative thresholds. Froh was
defined as the proportion of an individual’s genome that exists in
ROHs. Descriptive statistics of ROHs and Froh across individual
and combined datasets are shown in Table 1, and distribution of
ROH lengths and Froh are shown in Figure 1 (Figure S1 shows the
non-truncated distribution of Froh).
ROH burden results
We regressed case-control status on Froh separately in each of
the 17 datasets using logistic regression, controlling for potential
confounding factors such as population stratification and SNP
quality metrics (see Methods). Figure 2 shows the estimated change
in odds of schizophrenia for every 1% increase in Froh and the
95% confidence intervals from these 17 logistic regression
equations, and Figure S2 shows the same results from an analysis
conducted on the raw (non-imputed) SNP data. It should be noted
that confidence intervals are symmetric on the log odds scale but
Author Summary
Inbreeding occurs when genetic relatives have offspring.
Because all humans are related to one another, even if very
distantly, all people are inbred to various degrees. From a
genetic standpoint, it is well known that inbreeding
increases the risk that a child will have a rare recessive
genetic disease, but there is also increasing interest in
understanding whether inbreeding is a risk factor for more
common, complex disorders such as schizophrenia. In this
investigation, we used single-nucleotide polymorphism
data to quantify the degree to which 9,388 schizophrenia
cases and 12,456 controls were inbred, and we tested the
hypothesis that people whose genome shows higher
evidence of being inbred are at higher risk of having
schizophrenia. We estimate that the odds of schizophrenia
increase by,17% for every 1% increase in inbreeding. This
finding is consistent with a role for multiple recessive or
partially recessive alleles in the etiology of schizophrenia,
and it suggests that genetic variants that increase the risk
of schizophrenia have been selected against over evolu-
tionary time.
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asymmetric on the odds ratio scale shown in Figure 2 and Figure
S2. As indicated by the confidence intervals, there was a great deal
of variability in the estimates of the Froh-schizophrenia association,
and none of these 17 odds ratios significantly differed from one.
Nevertheless, 13 of the odds ratios were greater than one (i.e.,
consistent with autozygosity being a schizophrenia risk factor)
while 4 were less than one, a result inconsistent with chance (exact
binomial test, p=0.025). More formally, using a mixed linear
effects logistic regression model that treated dataset as a random
factor (which also controlled for SNP platform because dataset was
Table 1. Descriptive statistics of SNPs and ROHs (derived from imputed data) across datasets.
LD pruned % imputed avg Froh SD(Froh)
avg
ROH SD(ROH
Dataset n site platform
SNPs
passing QC
SNPs
passing QC
SNPs
genotyped * 100 *100
length
(kb) length in kb)
AB 1418 UK Affy 5 362461 180127 37% 0.13 0.21 2458 1897
BON 1778 Germany Illum 550 494953 269497 21% 0.11 0.17 2424 2055
BULG 1135 Bulgaria Affy 6 654278 288366 34% 0.21 0.45 3720 4014
CARWTC 3406 UK Affy 500 365456 184440 37% 0.12 0.37 2563 2629
CAT2 606 USA Affy 500 384538 234201 34% 0.18 1.05 3248 4107
DK 939 Denmark Illum 650 533191 277949 20% 0.14 0.36 2544 2766
DUB 1130 Ireland Affy 6 642723 271644 32% 0.16 0.21 2620 2237
EDI 650 UK Affy 6 646310 275252 32% 0.11 0.21 2413 2272
MGS2 5163 USA/Australia Affy 6 638937 280522 35% 0.11 0.21 2420 2021
MUC 785 Germany Illum 317 295593 202543 20% 0.14 0.39 2901 3317
PORT 561 Portugal Affy 5 333136 186277 39% 0.61 1.06 4662 4087
SW1 335 Sweden Affy 5 330113 170520 35% 0.19 0.31 2844 2593
SW2 618 Sweden Affy 6 661602 275690 31% 0.23 0.37 2911 2782
TOP3 598 Norway Affy 6 630195 280545 32% 0.15 0.17 2375 1575
UCLA 1334 Netherlands Illum 550 505922 270851 21% 0.15 0.37 2728 2681
UCL 1009 UK Affy 5 277652 156506 36% 0.09 0.13 2212 1633
ZHH 379 USA Affy 500 258470 159220 37% 0.36 0.99 3551 3385
Total 21844 N/A Imputed 398325 94812 82%{ 0.15 0.40 2788 2771
{82% of imputed SNPs used in overall ROH analysis were genotyped on at least one platform.
doi:10.1371/journal.pgen.1002656.t001
Figure 1. Distributions of ROH Lengths (left) and Froh (right) in the total sample. Distributions are based on ROHs from the imputed SNP
data. For clarity, the distribution of Froh leaves omits 15 individuals who have Froh..0625.
doi:10.1371/journal.pgen.1002656.g001
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nested within each platform), the overall association between
schizophrenia and Froh in the combined sample was highly
significant (b=16.1, z=3.44, p=0.0006 in the imputed data, and
b=17.98, z=3.89, p=0.0001 in the raw data). A slope of Froh on
schizophrenia of 16.1 is interpreted as saying that for every 0.01
increase in Froh, the odds of schizophrenia are multiplied by
e0:161~1:17, or increased by 17%.
Several secondary analyses were undertaken to explore the
robustness and generality of the Froh-schizophrenia association.
There was no evidence that the Froh-schizophrenia association
differed significantly between datasets (x2 =0.253, p=0.88), and
the association remained highly significant in 17 models that
removed one dataset at a time. To understand if this association
was sensitive to the covariates included in the model, we ran
additional models that controlled for no covariates, various
combinations of covariates, and dataset-by-covariate interactions.
In all of these models, the association between Froh and
schizophrenia remained significant. We also found that our
conclusions were insensitive to the SNP threshold used to define
ROHs; the association between Froh and schizophrenia remained
relatively unchanged and significant for all SNP thresholds of $40
consecutive SNPs in both the imputed (Figure 3) and raw (Figure
S3) data. Finally, both common ROHs (b=28.5, z=2.51,
p= .012), which arose from haplotypes that were observed often
in the data, and uncommon ROHs (b=20.4, z=3.29, p= .001)
were predictive of case-control status (see Methods).
Autozygosity versus hemizygosity
Copy number variant deletions can create apparent ROHs in
SNP data. We could not systematically catalog the overlap
between deletions and ROHs in the full dataset because deletion
information is not available on the entire sample. However,
Levinson and colleagues [41] identified 501,890 deletions (using
their ‘‘broad’’ criteria) in the MGS2 dataset (n=5,163), comprising
about one-fourth of the total sample used here. The median length
of a deletion in the MGS2 dataset was ,10 kb, whereas the
median length of a ROH was ,2,000 kb, suggesting that very few
deletions would be long enough to qualify as ROHs. Consistent
with this expectation, we found that only 10 of 6,480 ROHs in the
MGS2 dataset were possible deletions using the algorithm
described by McQuillan et al. [31], which called a ROH a
‘‘possible deletion’’ if its total length was ,500 kb after removing
deletion regions from ROHs. The percentage of ROHs thus
classified (0.15%) was similar to the percentage (0.30%) reported
by McQuillan et al. [31]. This percentage is too small to have a
meaningful impact on our results, because when we removed a
larger percentage of ROHs that were identified as being the largest
schizophrenia risk factors (see below), the Froh-schizophrenia
association remained highly significant. We conclude that ROH
results reported above are due to autozygosity rather than
hemizygosity.
The effects of close versus distant inbreeding on
schizophrenia
A reverse-causation explanation of the Froh-schizophrenia
association is possible: people who have a higher ‘‘load’’ of
schizophrenia risk alleles (and who transmit this risk to offspring)
may be more likely to mate with a relative. This counter-
explanation to the causal interpretation of the Froh-schizophrenia
relationship is less likely if the relationship holds not only for close
inbreeding, but also for autozygosity caused by distant and almost
certainly unintended inbreeding (arising from common ancestors
who lived many generations ago). One way to investigate this issue
is to remove positive outliers on Froh and reassess the Froh-
schizophrenia relationship. We reran models after dropping a) two
individuals with Froh.0.125, the approximate equivalent of half-
Figure 2. Estimated changes in odds of schizophrenia for each 1% increase in Froh (odds ratios; asterisks) and their 95% confidence
intervals (bars) across the 17 datasets (colored) and for the total sample (black) from the imputed SNP data. Boxes are proportional to
the square root of sample sizes (also shown at the bottom). Dataset names are on the x-axis. Although none of the estimated odds ratios are
significantly different from one individually, the overall effect (black) is highly significant.
doi:10.1371/journal.pgen.1002656.g002
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sibling inbreeding (b=15.57, 95% CI(b) = [25.0, 6.14], z=3.24,
p=0.001); b) 15 individuals with Froh.0.0625, the approximate
equivalent of cousin-cousin inbreeding (b=15.13, 95%
CI(b) = [26.1, 4.25], z=2.73, p=0.006); c) 56 individuals with
Froh.0.03125, the approximate equivalent of half-cousin inbreed-
ing (b=8.43, 95% CI(b) = [21.43, 24.55], z=1.27, p=0.20); d)
942 individuals with Froh..005, consistent with elevated levels of
distant inbreeding (b=5.17, 95% CI(b) = [34.84, 224.50],
z=0.34, p= .73); and e) 6,101 individuals with Froh scores above
the mean level of Froh (b=66.91, 95% CI(b) = [139.2, 25.4],
z=1.81, p= .07). To test whether the change in significance after
dropping outliers was due to the Froh-schizophrenia association
being stronger for individuals with high levels of autozygosity, we
included a quadratic term (Froh2) in the regression model. In
contrast to the highly significant linear term of Froh, the quadratic
term of Froh was non-significant (p= .09), suggesting that the effect
of autozygosity is linear across the range of Froh observed here.
The simple approach—dropping outliers—to distinguishing the
effects of distant versus close inbreeding is problematic for two
reasons. First, Froh is naturally extremely right-skewed (Figure 1
and Figure S1), even in large, simulated populations where close
inbreeding is disallowed [25], and so dropping even a small
number of outliers greatly reduces the variation in Froh, decreases
the statistical power to detect an association, and degrades the
precision of point estimates. Indeed, there is no evidence that the
schizophrenia-Froh association changes as outliers are removed,
because the original point estimate (b=16.1) is contained within
every confidence interval above. Thus, the results from dropping
outliers demonstrate that the Froh-schizophrenia relationship is not
driven by a few highly inbred individuals, but do not allow us to
distinguish the effects of distant vs. close inbreeding. Second,
individuals with high Froh can arise by chance from the
accumulation of many paths of distant inbreeding [25], and are
not necessarily the products of close inbreeding. For example, the
distribution of lengths of observed ROHs among individuals with
Froh.0.0625 is more consistent with inbreeding from common
ancestors living ,6 generations ago than with first cousin
inbreeding (Figure 4).
An alternative and more robust approach for assessing the
relative importance of distant versus close inbreeding is to
compare the effects of short versus long ROHs. We defined
Froh,5 Mb as the proportion of the autosome in ROHs of length
,5 Mb and Froh.5 Mb as the converse, with 5 Mb chosen as the
threshold because the variances of Froh,5 Mb and Froh.5 Mb
were equal. An autozygous segment spanning ,5 Mb should
originate from a common ancestor $10 generations ago on
average [41]. The effect of Froh,5 Mb (b=27.6, z=2.23,
p=0.026) was similar to the effect of Froh.5 Mb (b=24.3,
z=2.01, p=0.044), consistent with the hypothesis that autozyg-
osity arising from distant inbreeding is about as much of a
schizophrenia risk factor as autozygosity arising from more recent
common ancestors.
ROH mapping analysis
The top of Figure 5 shows the 2log10 p-values for the 5,742
logistic regressions predicting case-control status from ROHs at
each 500 kb bin along the autosome. No regions reached genome-
wide significance although two (1p13.2 and 3p24.1) exceeded the
‘‘suggestive significance’’ threshold. Table 2 shows the twelve
genes located in these two regions along with their potential
functional significances. Neither region has been previously
implicated in linkage analyses [42], copy number variant analyses
[43], or GWAS meta-analyses [3] of schizophrenia. After
recalculating Froh with the two suggestively significant regions
removed, results of the burden analysis remained essentially
unchanged, showing that these regions have only a minor
influence on the overall Froh-schizophrenia association and
suggesting that the effect of autozygosity is diffused across the
genome.
The bottom of Figure 5 shows the frequencies of ROHs
occurring at each 500 kb bin across the autosome. With one
exception, less than 1.5% of the sample had an ROH at each
Figure 3. Slope estimates (the change in log odds for a 1% increase in Froh; points) and their 95% confidence intervals (bars) of Froh
from imputed SNP data predicting schizophrenia for different SNP homozygosity thresholds of calling ROHs. Minimum SNP
thresholds for full and reduced models are offset for clarity. All ROH thresholds were significant; the most significant result was for ROHs defined as
being 65 or more homozygous SNPs in a row.
doi:10.1371/journal.pgen.1002656.g003
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region. The exception occurs in the Major Histocompatibility
Complex region in 6p21.3, where 15.5% of the sample had an
ROH. This high number of ROHs is explained by the low
recombination and long, common, geographically-specific haplo-
types that occur here [44,45].
Discussion
These results suggest that the odds of schizophrenia increase by
,17% for every 0.01 increase in the proportion of estimated
autosomal autozygosity (Froh). Given the standard deviation of Froh
(0.004), this effect is modest, explaining ,0.1% of the risk of
schizophrenia in outbred populations (Nagelkerke r=0.026).
Nevertheless, this effect implies that close inbreeding is a
significant risk factor for schizophrenia. Cousin-cousin inbreeding
is predicted to increase the odds of schizophrenia 2.74-fold (by
174%) and second-cousin inbreeding is expected to increase the
odds of schizophrenia 1.29-fold (by 29%). These estimates are
roughly in line with previous reports on schizophrenia from
samples selected based on pedigree inbreeding [15,16,17,18,19,20]
and similar to the increased risk of major birth defects following
close inbreeding [46]. Given that second cousin or closer
inbreeding occurs frequently in several world cultures, and that
progeny from such unions account for about 10% of the world’s
population [47], autozygosity may be an important risk factor for
schizophrenia worldwide.
The apparent effect of autozygosity on schizophrenia suggests
that risk alleles that are more dominant have disappeared over
evolutionary time at a faster rate than risk alleles that are more
recessive. This is consistent with the hypothesis that alleles that
increase the risk of schizophrenia have been under purifying
(negative) selection [48].
There are three main limitations to the current study. The most
important is that this was a mega-analysis of SNP data collected at
17 different sites using six different platforms. The collection and
handling of samples, the distribution of samples on plates, and the
calling of SNPs differed between and within sites in ways that were
impossible to quantify in the analysis. This certainly added noise to
the results, reducing the apparent effect size, but also may have
introduced subtle biases. We have tried to statistically control for
as many of these as possible, but the possibility remains that
uncorrected biases made these results appear stronger or weaker
than they actually are.
Figure 4. Distribution of ROH lengths for the 15 individuals with Froh..0625 in the sample (blue) and the expected lengths of
autozygous segments for different levels of inbreeding (red and orange). Nearby ROHs that were broken up by a possible heterozygous
SNP miscall were joined together. Assuming Haldane’s recombination model, the length of an autozygous segment should follow an exponential
distribution with mean equal to 1/(26number of generations since the common ancestor) in Morgans. The figure shows that the distribution of ROH
lengths among individuals with Froh..0625 is most consistent with autozygosity caused by common ancestors between parents who lived ,6
generations ago.
doi:10.1371/journal.pgen.1002656.g004
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Second, while our results clearly support the hypothesis that
autozygosity is a risk factor for schizophrenia, they are less clear
about how confidently we can differentiate the roles of distant
versus close inbreeding. On one hand, when enough outliers on
Froh values are excluded, the case-control difference is no longer
significant. On the other hand, there are good statistical reasons to
consider the analysis of short versus long ROHs more valid than
the analyses that exclude individuals with the highest Froh values.
Thus, the authors favor the conclusion that both distant and close
inbreeding are risk factors for schizophrenia. A more definitive
answer to this question would either require a substantially larger
sample size or a sample of similar size to the current one but
drawn from a population with greater variation in levels of distant
inbreeding.
A final limitation has to do with the correlational nature of these
findings. We argue that the Froh-schizophrenia association is likely
to be causal because the association is consistent with a known
genetic mechanism, directional dominance, and because the
Figure 5. Risk and protective effects of ROHs on schizophrenia risk and frequencies of ROHs across the autosome. Top panel: 2log10
p-values for the risk (red) and protective (blue) effects of ROHs on schizophrenia risk at each 500 kb region along the autosome. Bottom panel:
frequencies of ROHs across the autosome.
doi:10.1371/journal.pgen.1002656.g005
Table 2. Genes within the two 500 kb bins that reached ‘‘suggestive’’ significance in the ROH mapping analysis.
Gene Location Functional Significance
MRP63P1 1p13.2 mitochondrial ribosomal protein 63 pseudogene
LOC100421116 1p13.2 involved with trafficking protein, a kinesin binding 2 pseudogene
TRIM33 1p13.2 thought to be a transcriptional co-repressor
RPL26P10 1p13.2 ribosomal protein pseudogene
EIF2S2P5 1p13.2 subunit 2 beta pseudogene
LOC643586 1p13.2 pyruvate kinase, muscle pseudogene
BCAS2 1p13.2 believed to play a role in increasing estrogen receptor function
DENND2C 1p13.2 gene of unknown function; highly conserved across mammals
AMPD1 1p13.2 catalyzes deamination of AMP to IMP in skeletal muscle; role in the purine nucleotide cycle
RBMS3 3p24.1 encodes an RNA-binding protein; implicated in smoking cessation, diabetes, and bone mass
RPS12P5 3p24.1 pseudogene of unknown function
LOC100129900 3p24.1 pseudogene of unknown function
doi:10.1371/journal.pgen.1002656.t002
Runs of Homozygosity and Schizophrenia
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association appears to be as robust for short ROHs as long ROHs.
Short ROHs are likely to represent autozygosity caused by distant
inbreeding, and therefore seem less likely to differ between parents
as a function of their load of schizophrenia risk alleles.
Nevertheless, we cannot eliminate the possibility that parents of
offspring who have schizophrenia differ in ways that make distant
inbreeding more likely, such as an increased propensity to mate
with individuals who have culturally, geographically, or ethnically
similar backgrounds.
Conclusion
Inbreeding has had a central place in population genetics since
its inception, but until recently, the effects of inbreeding could only
be investigated from careful analysis of pedigrees and only for close
inbreeding. SNP data allows investigation into the effects of
potentially very distant inbreeding in non-selected samples, and
allows insight into where the signal comes from in the genome.
However, unless samples are specifically selected based on
inbreeding, very large samples are required to reliably detect
effects of autozygosity due to the low variation between individuals
in their levels of autozygosity. The present investigation used SNP
data from a large sample to conclude that autozygosity is a risk
factor for schizophrenia. If the relationship between Froh and
schizophrenia is due to directional dominance, such that
schizophrenia risk alleles are more recessive than otherwise
expected, this suggests that alleles that increase the risk of
schizophrenia have been under negative selection ancestrally.
Methods
Psychiatric GWAS consortium data
Full methods are given elsewhere [3]. Briefly, 9,388 schizo-
phrenia cases and 12,456 controls were collected with institutional
review board approval from 17 sites in 11 countries (Australia,
Bulgaria, Denmark, Germany, Ireland, Netherlands, Norway,
Portugal, Sweden, United Kingdom, and Unites States of
America; see Table 1). As is typical in the field, individuals with
schizophrenia or schizoaffective disorder were included as cases
[49] [50]. The quality of phenotypic data was verified by a
systematic review of data collection methods to ensure consistency
between sites.
Quality control (QC) procedures for raw SNP data
The initial set of samples and SNPs passed common GWAS QC
procedures [3]. In particular, we removed a) one individual from
any pair of individuals who were related with pi-hat .0.2, b)
individuals with non-European ancestry as determined by
principal components analysis; c) samples with SNP missingness
.0.02; or d) samples with genome-wide heterozygosities .6
standard deviations above the mean. SNPs were excluded if they a)
deviated from Hardy-Weinberg equilibrium at p,161026; b) had
missingness .0.02; c) showed a minor allele frequency difference
to HapMap CEU.0.15; or d) had a missingness difference
between cases and controls .0.02. On average the QC processes
excluded 15 individuals (0–100) and 38K SNPs (5K–160K) per
dataset. The number of SNPs per dataset after QC varied between
250K and 680K (Table 1).
Imputation and QC procedures for imputed SNP data
Six different SNP platforms (Affymetrix 500K, 5.0, and 6.0
chips along with the Illumina 317K, 550K, and 650K chips;
Table 1) were used across the 17 datasets. Differences across
platforms in SNP densities, frequency distributions, LD patterns,
and missingness led to variation in ROH statistics across datasets.
For example, the DK dataset contains 280K SNPs after LD
pruning (1 SNP per 11 kb) whereas the UCL datset contains 156K
SNPs after LD pruning (1 SNP per 21 kb). ROHs therefore would
have to be about twice as long in the UCL dataset to qualify,
which induces artifactual noise in ROH statistics due to platform
effects. This issue is not circumvented by using an ROH threshold
based on length rather than number of SNPs; in this case, half as
many homozygous SNPs in a row would be required to call an
ROH in the less dense dataset. In both cases, the type-I and type-
II error rates of autozygosity detection differ systematically
between datasets.
To overcome these issues, we imputed dosages for 1,252,901
autosomal SNPs in each dataset using BEAGLE [38] and
HapMap3 as the reference panel [3]. We converted imputation
dosages to best-guess (highest posterior probability) SNP calls
because ROH detection algorithms require discrete SNP calls.
Because typical imputation QC thresholds can lead to a high
number of missed ROHs, we used extremely stringent imputation
QC thresholds that have been shown to achieve accuracy rates
similar to those in genotyped SNPs [39]. In particular, we
removed 854,566 imputed SNPs with dosage r2,0.90 in any
dataset (the dosage r2 is equivalent to MACH’s r2 measure
described in [51]), that had a dosage r2,0.98 or .1.02 in the
overall sample, or that had MAF,0.05, leaving 398,325 high-
quality imputed SNPs. Because only,100K SNPs are use to make
ROH calls (see below), we could afford to lose a large number of
imputed SNPs from QC procedures.
ROHs called from imputed data were less variable across
platform and across datasets in terms of basic descriptive statistics,
in the effects of potential artifacts (e.g., SNP missingness rates and
excess heterozygosity on Froh), and in their associations with
schizophrenia. We therefore report results on ROHs called from
imputed data. However, results for the ROHs called from raw
data were similar, and are shown in Figures S2 and S3.
ROH calling procedures
Of three programs investigated (PLINK, GERMLINE, and
BEAGLE), a recent investigation by three of the authors of the
current report [40] concluded that PLINK (using the –homozyg
commands) optimally detected autozygous stretches and maxi-
mized power to detect an effect of autozygosity on a phenotype. In
particular, the authors recommended: a) pruning for strong LD
(removing any SNPs having a multiple R2.0.90 with all other
SNPs in a 50 SNP window), which reduced false autozygosity calls
by removing redundant markers in SNP-dense regions and by
making SNP coverage more uniform; and b) defining ROHs as
being $65 consecutive homozygous SNPs with no heterozygote
calls allowed [40]. We used these recommendations to detect
ROHs in all analyses, although to ensure that we did not miss
potential effects of autozygosity, we report on results from the
specific ROH threshold (number of homozygous SNPs in a row)
that minimized the p-value of the Froh-schizophrenia association
(see Figure 3 and Figure S3). This threshold was 65 SNPs-in-a-row
(spanning ,2.3 Mb) in the imputed SNP data and 110 SNPs-in-a-
row (spanning ,1.7 Mb to ,3.2 Mb depending on the dataset) in
the raw data. It should be noted that results were relatively
insensitive to the specific threshold chosen (Figure 3 and Figure
S3). Finally, to ensure that no ROH crossed a region of low SNP
density (e.g., a centromere), we also required that ROHs have a
density greater than 1 SNP per 200 kb, and we broke an ROH in
two if a gap.500 kb existed between adjacent homozygous SNPs.
ROHs can also be categorized by their frequency (how often a
particular haplotype creates ROHs at a given location). We used
PLINK’s –homozyg-group and –homozyg-match arguments to
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understand whether uncommon ROHs or common ROHs were
particularly predictive of case-control status, defining ROHs in a
given region as ‘‘uncommon’’ when they allelically matched with
16 (the median) or fewer other ROHs in the combined data; all
other ROHs were defined as ‘‘common.’’
ROH burden analysis
For each individual, we summed the total length of all their
ROHs in the autosome and divided by the total SNP-mappable
autosomal distance (2.776109 bases) to derive Froh, the proportion
(0 to 1) of the autosome in ROHs. Froh was used as the predictor of
case-control status in ROH burden analyses. Froh can be
influenced by confounding factors like population stratification
(e.g., if background levels of heterozygosity or autozygosity differed
by ancestry), low quality DNA leading to incorrect SNP calls, and
heterozygosity levels that vary across plates, DNA sources, etc. To
control for the effects of stratification, we included the first 20
principal components based on ,30K SNPs genotyped in all
datasets. We also controlled for the percentage of missing calls in
the raw SNP data and excess heterozygosity as these track the
quality of SNP calls [52]. Using simulations, Keller et al. [25]
showed that the ability of Froh to accurately estimate autozygosity
is negligibly affected by statistically controlling for excess
heterozygosity, and therefore doing so should have minimal effect
on results when genotyping error rates are low, but may help
elucidate effects of ROHs when such errors are present.
We regressed case-control status on Froh separately in each of
the 17 datasets using logistic regression, controlling for the
potential confounders discussed above. We then employed a
mixed linear effects logistic regression model (using the lme4
package in R version 2.11) to estimate the overall effect of Froh
across datasets, treating dataset as a random factor. This also
controlled for SNP platform because dataset was nested within
each platform (controlling for platform was statistically redundant
in a model also controlling for dataset).
ROH mapping analysis
To understand whether any genomic area was predictive of
case-control status, we divided the autosome into 5,742 segments
of length 500 kb each. At each segment, an individual was scored
as either having a ROH that partially or completely overlapped
the segment or not. We performed 5,742 logistic regressions,
regressing case-control status on whether or not individuals had an
ROH in each segment, controlling for covariates described above.
To derive a genome-wide significance threshold corrected for
multiple testing, we permuted case-control status within the 17
datasets and reran the 5,742 logistic regressions, preserving the
most significant result of each permutation. We repeated this
permutation 1,000 times. The 50th most significant p-value was
the genome-wide significance threshold and the 100th most
significant p-value was the ‘‘suggestive’’ genome-wide significance
threshold.
Supporting Information
Figure S1 Distributions of ROH Lengths (left) and Froh (right) in
the total sample, including individuals with Froh..0625. Distribu-
tions are based on ROHs from the imputed SNP data.
(TIF)
Figure S2 Estimated changes in odds of schizophrenia for each
1% increase in Froh (odds ratios; asterisks) and their 95%
confidence intervals (bars) across the 17 datasets (colored) and
for the total sample (black) from the raw SNP data. Boxes are
proportional to the square root of sample sizes (also shown at the
bottom). Dataset names are on the x-axis. Although none of the
estimated odds ratios are significantly different from one
individually, the overall effect (black) is highly significant.
(TIF)
Figure S3 Slope estimates (the change in log odds for a 1%
increase in Froh; points) and their 95% confidence intervals (bars)
of Froh from raw SNP data predicting schizophrenia for different
SNP homozygosity thresholds of calling ROHs. Minimum SNP
thresholds for full and reduced models are offset for clarity. All
ROH thresholds were significant; the most significant result was
for ROHs defined as being 110 or more homozygous SNPs in a
row.
(TIF)
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